Avik Roy 
Senior fellow at the Manhattan Institute and author of the Apothecary, a health-policy blog at Forbes.com.
Category: Management Fundamentals
Web Sites:
blogs.forbes.com/aroy/
blogs.forbes.com/aroy/
Interviews with Avik Roy»See all
Should U.S. drug companies benefit from European testing results? Avik Roy joins Jim Blasingame to compare the U.S. and European drug testing systems to bring new drugs to the market, plus the added costs of litigation.
Can FDA approval for new drugs become less onerous? Avik Roy joins Jim Blasingame to report on the high costs of FDA-required clinical trials and the advantages of an accelerated trial program.
The cost of taking a new drug to market is over ten times more today than in 1975. Avik Roy joins Jim Blasingame to report on the cost of complying with current FDA regulations is making new drug development prohibitive.
